Bedaquiline 100 mg

DRUG2 trials

Sponsors

Médecins Sans Frontières, France, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Bacterial InfectionsGram-Positive Bacterial InfectionsMycobacterial InfectionsPulmonary TuberculosesTuberculosisTuberculosis, Multidrug-ResistantTuberculosis, Pulmonary

Phase 2

Linezolid Dosing Strategies in Drug-Resistant TB

Active, not recruitingNCT05007821

National Institute of Allergy and Infectious Diseases (NIAID)Tuberculosis, Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary

Start: 2022-08-11End: 2026-03-13Updated: 2025-08-12

Phase 3

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)

CompletedNCT03896685

Médecins Sans Frontières, FranceBacterial Infections, Gram-Positive Bacterial Infections, Mycobacterial Infections +3

Start: 2020-04-06End: 2024-12-31Updated: 2025-02-10

Related Papers

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.

2025-07-166 citations

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.

2023-11-3012 citations

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.

2021-09-2522 citations